1. Scrip
  2. >>Business

BIOSECURE Act Diluted Significantly, But China Plus Strategy Still Accelerating: Strides MD

Significant growth expected in H2 FY25

 
• By Vibha Ravi

A time extension to US companies to shift business away from a few Chinese firms under the proposed BIOSECURE Act has disappointed the Strides MD. However, the China plus strategy continues to drive business and capacity expansion for auto-injectors required by GLP-1 customers is expected

Simmering US-China Tensions Are Leading To Business Rebalancing
Simmering US-China Relations Necessitate Business Rebalancing • Source: Shutterstiock

US lawmakers had business realities and industry requests in mind when they amended the BIOSECURE Bill allowing US companies time till 2032 to shift business away from select Chinese ones, but that has disappointed Indian contract development and manufacturing (CDMO) firms.

“The BIOSECURE Act has been diluted quite significantly and there is now a seven-to-eight-year window for the companies dependent on China to find alternative solutions,” Strides Pharma Science Limited managing director Arun Kumar said in

More from Business

More from Scrip

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.